A top-50 pharma delivered 10 IgG candidates meeting potency and developability criteria after earlier campaigns failed.

An IgG program had stalled because prior efforts could not meet potency and developability criteria together, and the parent had two sequence liabilities. Cradle ran three rounds of 96 candidates, trained on data from the failed campaigns and optimizing all properties at once. The page reports 10 candidates meeting all criteria advanced to the next stage, with both liabilities removed.

Cradle is an AI protein engineering software company whose platform designs and optimizes proteins, antibodies, enzymes and peptides for biopharma and industry.

This sits in the Design & Stress-Test stage of the AI use-case lifecycle: Named examples from the tools pharma teams use to scope, prototype and benchmark an AI use case before committing to build it — data-catalog, sandbox and evaluation platforms.